Business Development Manager
Seer InteractiveFull Time
Senior (5 to 8 years), Expert & Leadership (9+ years)
Candidates should possess 4+ years of commercial experience in biotechnology, CDMO/CRO services, or life sciences tools organizations, with a total of 8 years in the biotechnology, bioproduction, or life sciences industries. A proven track record in selling bespoke technical services, navigating complex sales cycles, and a deep understanding of the biotherapeutics manufacturing landscape are essential. Strong networking skills within the biopharma services and tools market, demonstrated expertise in growing long-term client relationships, and technical acumen in cell line development, CMC, process development, and biologics/viral vector manufacturing are required. A scientific or technical background in life sciences is preferred, with advanced degrees being a plus.
The Business Development Manager will drive revenue growth by developing and executing territory expansion strategies to secure new opportunities and increase market presence within the European biopharma ecosystem. They will build and nurture client relationships, effectively communicate Asimov's platform technologies and their benefits, and own the commercial deal process by shaping partnership strategy and developing deal structures. Additionally, the role involves representing Asimov at industry events to enhance visibility and reputation, and contributing to a collaborative culture by sharing insights and supporting peers.
Synthetic biology solutions for biopharmaceuticals
Asimov operates in the synthetic biology field, providing a combination of cells, genes, and software to assist in advanced genetic design. Their products include cloud-based software that allows clients in the biopharmaceutical industry to design, simulate, and optimize genetic systems. Additionally, they offer engineered GMP host cells that are used for therapeutic applications. Asimov distinguishes itself from competitors by guaranteeing high titer cell lines for monoclonal antibodies with a promise of '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to produce high-quality protein therapeutics and scalable viral vectors efficiently, supported by their in-house expertise in synthetic biology and process development.